Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

AstraZeneca and Merck & Co’s Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday. BRCA mutations are typically linked with breast and ovarian cancers, but occur in other cancers as well. Lynparza was tested against a placebo as a maintenance therapy in 154 patients with metastatic pancreatic cancer whose tumors had not progressed after chemotherapy.

Source: Yahoo.com